Dr Karen Mactier
- Clinical Research Fellow (Clinical Research Garscube)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Thapa, A. et al. (2024) The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland. Clinical Oncology, 36(5), pp. 287-299. (doi: 10.1016/j.clon.2024.02.004) (PMID:38395634)
Thapa, A. et al. (2024) The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland. Clinical Oncology, 36(5), pp. 287-299. (doi: 10.1016/j.clon.2024.02.004) (PMID:38395634)
https://orcid.org/0000-0003-1202-8548